argenx SE reported $8.07B in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AstraZeneca USD 31.45B 3.48B Sep/2026
Genmab DKK 2.8B 228M Jun/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
GRIFOLS EUR 5.35B 40M Sep/2026
Hikma Pharmaceutical USD 2.64B 86M Dec/2025
Lakefront Biotherapeutics EUR 2.25B 61.23M Sep/2026
Qiagen NV USD 1.66B 116.37M Jun/2026
UCB EUR 6.05B 733M Dec/2025